# Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.

> **NCT06099119** · PHASE4 · RECRUITING · sponsor: **Hospital Clinico Universitario de Santiago** · enrollment: 100 (estimated)

## Conditions studied

- Unresectable Pancreatic Cancer

## Interventions

- **DRUG:** creon 35.000 Ph.U (R)
- **OTHER:** Best Standarard of Care

## Key facts

- **NCT ID:** NCT06099119
- **Lead sponsor:** Hospital Clinico Universitario de Santiago
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-20
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06099119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06099119, "Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06099119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*